1. Rebooting twitter (last tweet 7yrs ago!) for lab, now an apt time for intro #threads on Lok lab's bckgrnd. Mission is to improve the outcomes of lung cancer patients by developing novel therapeutic strategies(esp. related to DNA repair) + understanding resistance mechanisms
Researchers at @PMResearch_UHN have identified a potential new target to enhance radiation therapy for #SmallCellLungCancer.
Blocking HDAC3 protein function makes cancer cells more sensitive to radiation.
🔗 Read more: https://t.co/98WNq5wV6g
A team led by Dr. @BenLok@UHN has found a new target to enhance radiation therapy in small cell lung cancer. By removing the function of gene HDAC3, cancer cells became more sensitive to radiation and tumour growth was inhibited:
https://t.co/aIPDy9kYky;
https://t.co/CgOONdnsii
🧬 The team also found that PRMT inhibitor could improve SCLC treatment outcomes from an epigenetic point of view: A PRMT inhibitor (MS023) disrupts splicing, increases DNA damage & shows strong synergy with chemo & radiation.
Published in Neoplasia: https://t.co/4r60aOwsWC
🔬 New strategy to boost immunotherapy for small cell lung cancer (SCLC): Combining PARP inhibitors + radiotherapy activates immune pathways & boosts T cell-attracting chemokines, discovered by @BenLok’s team at @UHN@pmcancercentre.
Read in @NatureComms: https://t.co/0TZpb86kQX
Our latest lab paper is here!
"PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer"
https://t.co/QeCRxNeAxz
https://t.co/D5Nh4NAzK5
@NatureComms
1/3
How do immunogenic radiosensitizers work?
Unexpectedly, we found they also decrease a mRNA degrader, EIF4E2, ultimately contributing to increased T cell attractant chemokines and immunotherapy efficacy in preclinical models.
2/3
Is PARPi safe with consolidative RT in ES-SCLC?
🔊Seems so
Ph1 presented by @BenLok at #ASTRO24 of Talazoparib concurrent with RT.
👉MTD of talazoparib with RT is 1 mg
👉5% Grade 3 and 55% Grade 1-2 oesophagitis
👉No new safety signals
⏭️Future combos with IO and BiTEs
#ASTRO24
Terrific early morning #lungcancer session🫁‼️
@BenLok reporting on tolerability of PARPi with IMRT as consolidation in patients with ES-SCLC🙏
Important to restrict esophagitis‼️
Excellent basis for future development of PARPi in this space👍 #LCSM
Welcome to Advances in Radiation Oncology's X account! Follow us here to read about the latest advances in our field and to learn about innovative scholarship emerging from our specialty! #ASTRO24
This week marks 1 year since we initiated NET tissue biobanking. Today, we received tissue samples from the 40th patient.
We want to take this opportunity to express our deep gratitude to all the patients who have generously donated samples.
@HalletJulie@CureNETs@tfri_research